-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D Hill, P Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin Jr, Jennifer S Li
Clinical Trail Prospective: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomes: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Corrigendum: Clin Invest (2011) 1(1) 145156.
Editor\\\'s Note: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation
-
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Esther V Hobson,Basil Sharrack
Review Article: Clinical Investigation